When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory. At StockStory, we look beyond the headlines with our independent analysis to determine whether these bearish calls are justified. Keeping that in mind, here is one stock poised to prove Wall Street wrong and two where the outlook is warranted. Two Stocks to Sell: Playa Hotels & Resorts (PLYA) Consensus Price Target: $13.46 (0.2% implied return) Sporting a roster of beachfront properties, Playa Hotels & Resorts (NASDAQ:PLYA) is an owner, operator, and developer of all-inclusive resorts in prime vacation destinations. Why Are We Cautious About PLYA? Softer revenue per room over the past two years suggests it might have to invest in new amenities such as restaurants and bars to attract customers Estimated sales decline of 2.6% for the next 12 months implies an even more challenging demand environment ROIC of 4.4% reflects management’s challenges in identifying attractive investment opportunities Playa Hotels & Resorts is trading at $13.43 per share, or 21.6x forward P/E. Read our free research report to see why you should think twice about including PLYA in your portfolio, it’s free. 3M (MMM) Consensus Price Target: $148.20 (5.1% implied return) Producers of the first asthma inhaler, 3M Company (NYSE:MMM) is a global conglomerate known for products in industries like healthcare, safety, electronics, and consumer goods. Why Do We Pass on MMM? Organic revenue growth fell short of our benchmarks over the past two years and implies it may need to improve its products, pricing, or go-to-market strategy Earnings per share have contracted by 3.4% annually over the last five years, a headwind for returns as stock prices often echo long-term EPS performance Shrinking returns on capital from an already weak position reveal that neither previous nor ongoing investments are yielding the desired results At $141 per share, 3M trades at 17.7x forward P/E. Check out our free in-depth research report to learn more about why MMM doesn’t pass our bar. One Stock to Watch: Cardinal Health (CAH) Consensus Price Target: $154.74 (1.1% implied return) Operating as a critical link in the healthcare supply chain since 1979, Cardinal Health (NYSE:CAH) distributes pharmaceuticals and manufactures medical products for hospitals, pharmacies, and healthcare providers across the global healthcare supply chain. Why Do We Like CAH? Dominant market position is represented by its $222.3 billion in revenue, which creates significant barriers to entry in this highly regulated industry Estimated revenue growth of 8.4% for the next 12 months implies demand will accelerate from its two-year trend Earnings per share grew by 7.7% annually over the last five years and topped the peer group average Story Continues Cardinal Health’s stock price of $153.13 implies a valuation ratio of 17.6x forward P/E. Is now the right time to buy? Find out in our full research report, it’s free. Stocks That Overcame Trump’s 2018 Tariffs The market surged in 2024 and reached record highs after Donald Trump’s presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we’re homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver’s seat and build a durable portfolio by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 175% over the last five years. Stocks that made our list in 2019 include now familiar names such as Nvidia (+2,183% between December 2019 and December 2024) as well as under-the-radar businesses like Axon (+711% five-year return). Find your next big winner with StockStory today for free. View Comments
1 Hated Stock that Deserves Some Love and 2 to Question
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research.
Start Your Free Trial Now!Not sure where to invest today?
Kalkine’s latest research highlights three companies identified through in-depth analysis and market insights.
Explore these research reports to learn about companies currently being tracked by our analysts and make more informed investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...